Recent advances in understanding Crimean-Congo hemorrhagic fever virus

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
Crimean-Congo hemorrhagic fever 1 infectiousdiseases
Lassa fever 1 infectiousdiseases
diarrhea 1 infectiousdiseases
ribavirin 19 infectiousdiseasesdrugs
vaccinia 3 infectiousdiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
ribavirin 22853 World Health Organization for the treatment of CCHFV. However, clinical data supporting the use of ribavirin to treat CCHF are inconsistent; some studies report benefits whereas others report no benefit, and meta-analyses
ribavirin 23025 whereas others report no benefit, and meta-analyses of multiple studies suggest that the efficacy of ribavirin is poor or inconclusive [69]– [71]. Notably, a placebo-controlled study failed to identify a clinical
ribavirin 23150 inconclusive [69]– [71]. Notably, a placebo-controlled study failed to identify a clinical benefit of ribavirin treatment in patients with CCHF [72]. A recent meta-analysis demonstrated that ribavirin treatment needs
ribavirin 23239 benefit of ribavirin treatment in patients with CCHF [72]. A recent meta-analysis demonstrated that ribavirin treatment needs to be started soon after symptom onset (<48 hours) to reduce odds of death [73]. In
ribavirin 23434 death [73]. In the recent emergence of CCHFV in Spain, although treatment of an infected nurse with ribavirin had mutagenic effects on CCHFV in vivo and a reduction in viral titers was coincident with treatment
ribavirin 23568 CCHFV in vivo and a reduction in viral titers was coincident with treatment start [74], ultimately ribavirin treatment was discontinued because of suspected hemolytic anemia [75], a potential complication of ribavirin
ribavirin 23677 treatment was discontinued because of suspected hemolytic anemia [75], a potential complication of ribavirin treatment [76], [77]. The inconsistent data on the clinical benefit of ribavirin for the treatment of
ribavirin 23758 potential complication of ribavirin treatment [76], [77]. The inconsistent data on the clinical benefit of ribavirin for the treatment of CCHFV and the potential for adverse events with ribavirin treatment have caused
ribavirin 23837 clinical benefit of ribavirin for the treatment of CCHFV and the potential for adverse events with ribavirin treatment have caused significant debate in the field [78]– [81]. Ethical considerations of placebo-controlled
ribavirin 24083 make further studies of this type difficult [82], preventing definitive conclusions on the efficacy of ribavirin in patients with CCHF.Studies in mouse models have also shown inconsistent efficacy of ribavirin. Two
ribavirin 24180 of ribavirin in patients with CCHF.Studies in mouse models have also shown inconsistent efficacy of ribavirin . Two studies have shown that even early treatment with ribavirin (<6 hours PI) was unable to prevent
ribavirin 24245 also shown inconsistent efficacy of ribavirin. Two studies have shown that even early treatment with ribavirin (<6 hours PI) was unable to prevent lethal disease following infection with two distinct clinical isolates
ribavirin 24418 infection with two distinct clinical isolates of CCHFV [53], [54]. However, another study showed that ribavirin could protect against lethal disease following CCHFV strain 10200 infection when administered early
ribavirin 24681 delayed or challenge dose was increased [25]. However, results from our lab showed that although early ribavirin treatment extended the mean time to death, ribavirin was unable to prevent death in 10200-infected mice [54].
ribavirin 24734 results from our lab showed that although early ribavirin treatment extended the mean time to death, ribavirin was unable to prevent death in 10200-infected mice [54]. The reason for the distinct outcomes in ribavirin-treated
ribavirin 24841 ribavirin was unable to prevent death in 10200-infected mice [54]. The reason for the distinct outcomes in ribavirin -treated strain 10200-infected mice seen between our study [54] and that by Bente et al. [25] is unknown
ribavirin 25165 time treatment was started after infection. Cumulatively, data in humans and mice suggest that while ribavirin may have limited clinical benefit in patients with CCHF, treatment likely needs to be started early
ribavirin 26462 for the treatment of advanced CCHF. Furthermore, Oestereich et al. demonstrated that favipiravir and ribavirin could synergistically inhibit CCHFV in vitro, allowing lower doses of both drugs to be used in vivo
ribavirin 26958 compound, 2′-deoxy-2′-fluorocytidine, with inhibitory activity superior to that of favipiravir or ribavirin in vitro[88]. In vivo animal studies will be needed to evaluate how this compound performs in animal
Select Disease Character Offset Disease Term Instance
Crimean-Congo hemorrhagic fever 374 (Writing – Review & Editing)Publication date (epub): 10/2018Publication date (collection): /2018Abstract Crimean-Congo hemorrhagic fever virus (CCHFV) is a widely distributed hemorrhagic fever virus and the cause of hemorrhagic disease in
Lassa fever 26757 effective in treating CCHF while reducing unwanted side effects [53]. A similar approach has been used in Lassa fever cases [87]. In addition, a high-throughput screen using recombinant CCHFV identified a compound, 2′-deoxy-2′-fluorocytidine,
diarrhea 5891 of CCHF are a non-specific febrile illness that can occur suddenly. Sudden onset of fever, myalgia, diarrhea , nausea, and vomiting is typically reported. After this, patients enter the hemorrhagic period in which
vaccinia 11952 antibodies can be protective via mechanisms other than neutralization. Studies evaluating a modified vaccinia virus-based vaccine for CCHFV found protection to require both cellular and humoral responses, suggesting
vaccinia 20851 ( http://www.cchfvaccine.eu/), and several vaccines have shown promise in pre-clinical trials. A modified vaccinia virus expressing the glycoproteins of CCHFV was shown to provide 100% protection to lethally challenged
vaccinia 22154 nucleoprotein can be protective independently of responses to the glycoproteins. However, a modified vaccinia virus expressing the nucleoprotein of CCHFV, though immunogenic, failed to protect against lethal CCHFV

You must be authorized to submit a review.